1
|
Kim JH, Lee DE, Ha HI, Jung JY, Kim SH, Lee HH, Seo HK, Seo SS, Kang S, Park SY, Lim MC. Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study. BMC Cancer 2022; 22:1163. [PMID: 36357914 PMCID: PMC9650832 DOI: 10.1186/s12885-022-10288-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 09/20/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Ureteral reconstruction is required after surgical resection of the tumor invading the urinary tract in ovarian cancer with low incidence. There are no currently reported surgical outcomes of ureteral reconstruction during cytoreductive surgery. The aim of the study is to investigate the clinical features and surgical outcomes of ureteral reconstruction during primary, interval and secondary cytoreductive surgery for ovarian cancer. METHODS: A total of 3226 patients who underwent primary, interval or secondary cytoreductive surgery for ovarian cancer between January 2000 and May 2021 were reviewed. Fifty-six patients who underwent ureteral reconstruction during cytoreductive surgery were included in the analysis. RESULTS: Ureteral reconstruction was required in 1.7% (56/3226) of ovarian cancer patients. Of the 56 patients who underwent ureteral reconstruction during cytoreductive surgery, 35 (62.5%) had primary ovarian cancer, and 21 (37.5%) had recurrent ovarian cancer. The median tumor size invading the lower urinary tract was 2.0 cm (range, 0.4-9.5 cm). Ureteroneocystostomy with direct implantation (51.8%) and psoas hitch (8.9%), transureteroureterostomy (7.1%), and ureteroureterostomy (32.1%) were required as part of cytoreductive surgery. Complete cytoreduction with ureteral reconstruction was achieved in 83.9% (47/56) and the rest of the patient population (16.1%) achieved a gross residual tumor size of less than 1 cm. All complications, including hydronephrosis (33.9%), were managed, none resulting in long-term sequelae. In primary ovarian cancer, the 5-year disease-free survival and overall survival were 50.0% and 89.5%, respectively. In patients with recurrent ovarian cancer, the 5-year disease-free survival and overall survival were 23.6% and 64.0%, respectively. CONCLUSIONS Ureteral reconstruction as a part of cytoreductive surgery for ovarian cancer could be performed with acceptable morbidities. Complete cytoreduction by a multidisciplinary surgical team, including urologic oncologists, should be pursued for the surgical management of ovarian cancer. TRIAL REGISTRATION Retrospectively registered.
Collapse
Affiliation(s)
- Ji Hyun Kim
- Center for Gynecologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Gyeonggi-Do, Goyang-Si, 10408, Republic of Korea
| | - Dong-Eun Lee
- Biostatistics Collaboration Team, National Cancer Center, Goyang, Republic of Korea
| | - Hyeong In Ha
- Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea
| | - Jae Young Jung
- Department of Urology, National Cancer Center, Goyang, Republic of Korea
- Center for Clinical Trials, National Cancer Center, Goyang, Republic of Korea
| | - Sung Han Kim
- Department of Urology, National Cancer Center, Goyang, Republic of Korea
| | - Hyung Ho Lee
- Department of Urology, National Cancer Center, Goyang, Republic of Korea
| | - Ho Kyung Seo
- Department of Urology, National Cancer Center, Goyang, Republic of Korea
- Department of Tumor Immunology, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea
| | - Sang-Soo Seo
- Center for Gynecologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Gyeonggi-Do, Goyang-Si, 10408, Republic of Korea
| | - Sokbom Kang
- Center for Gynecologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Gyeonggi-Do, Goyang-Si, 10408, Republic of Korea
| | - Sang-Yoon Park
- Center for Gynecologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Gyeonggi-Do, Goyang-Si, 10408, Republic of Korea
| | - Myong Cheol Lim
- Center for Gynecologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Gyeonggi-Do, Goyang-Si, 10408, Republic of Korea.
- Center for Clinical Trials, National Cancer Center, Goyang, Republic of Korea.
- Department of Tumor Immunology, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
- Rare and Pediatric Cancer Branch and Immuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
| |
Collapse
|
2
|
Martin A, Wells A, Anderson ML, Chern JY, Rutherford TJ, Shahzad MM, Wenham RM, Hoffman MS. Trends in ureteral surgery on an academic gynecologic oncology service. Gynecol Oncol 2021; 163:552-556. [PMID: 34674890 DOI: 10.1016/j.ygyno.2021.10.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 10/05/2021] [Accepted: 10/08/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To describe the incidence, complications, and trends associated with ureteral surgeries on a gynecologic oncology service in the context of a fellowship training program over a 24-year period. METHODS We conducted a retrospective cohort analysis of ureteral surgeries by gynecologic oncologists at either Moffitt Cancer Center or Tampa General Hospital from 1997 to 2020. Patient characteristics, predisposing factors, location and type of injury, repair method, postoperative management and complications were abstracted from the medical record. The recent cohort (2005-2020) was compared to our prior series (1997-2004). RESULTS Eighty-eight cases were included. The average number of ureteral surgeries per year decreased from 5.75 (1997-2004) to 2.63 (2005-2020). Of 46 iatrogenic injuries, 45 were recognized and repaired intraoperatively. Ureteral transection was the most common type (85% [39 of 46]) and the distal 5 cm was the most common location of injury (63% [29 of 46]). Ureteroneocystostomy was the most common method of repair (83% [73 of 88]). Postoperative management, including stenting and imaging, has not changed significantly. Length of urinary catheter usage decreased in the recent cohort without associated complications. Five patients had major postoperative complications and 4 involved the urinary tract. Of those with follow-up, 96% (66 of 69) of ureteroneocystostomies and 75% (9 of 12) of ureteroureterostomies had radiologically normal urinary tracts. CONCLUSIONS Ureteral surgery is necessary in the case of injury or involvement with invasive disease. There has been a decrease in number of procedures. Ureteroneocystostomy has remained the most common method of reconstruction for both injury and resection with acceptable postoperative complication rates.
Collapse
Affiliation(s)
- Alexandra Martin
- Department of Clinical Science, Moffitt Cancer Center, University of South Florida, Tampa, FL, United States of America.
| | - Ali Wells
- Department of Obstetrics & Gynecology, University of South Florida College of Medicine, Tampa, FL, United States of America
| | - Matthew L Anderson
- Division of Gynecologic Oncology, University of South Florida College of Medicine, Tampa, FL, United States of America
| | - Jing-Yi Chern
- H. Lee Moffitt Cancer Center, Department of Gynecologic Oncology, Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States of America
| | - Thomas J Rutherford
- Division of Gynecologic Oncology, University of South Florida College of Medicine, Tampa, FL, United States of America
| | - Mian M Shahzad
- H. Lee Moffitt Cancer Center, Department of Gynecologic Oncology, Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States of America
| | - Robert M Wenham
- H. Lee Moffitt Cancer Center, Department of Gynecologic Oncology, Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States of America
| | - Mitchel S Hoffman
- H. Lee Moffitt Cancer Center, Department of Gynecologic Oncology, Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States of America
| |
Collapse
|